Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas.

Tytuł:
Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas.
Autorzy:
Lominska CE; Department of Radiation Oncology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA. />Unger K
Nasr NM
Haddad N
Gagnon G
Źródło:
Radiation oncology (London, England) [Radiat Oncol] 2012 May 18; Vol. 7, pp. 74. Date of Electronic Publication: 2012 May 18.
Typ publikacji:
Evaluation Study; Journal Article
Język:
English
Imprint Name(s):
Original Publication: [London] : BioMed Central, 2006-
MeSH Terms:
Radiosurgery*/methods
Adenocarcinoma/*surgery
Pancreatic Neoplasms/*surgery
Adenocarcinoma/mortality ; Adenocarcinoma/radiotherapy ; Adult ; Aged ; Aged, 80 and over ; Dose Fractionation, Radiation ; Female ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/radiotherapy ; Radiation Dosage ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Analysis
References:
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42. (PMID: 20171803)
Arch Surg. 1985 Aug;120(8):899-903. (PMID: 4015380)
N Engl J Med. 2004 Mar 18;350(12):1200-10. (PMID: 15028824)
Cancer. 1976 Mar;37(3):1519-24. (PMID: 1260670)
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):678-86. (PMID: 18395362)
JAMA. 2007 Jan 17;297(3):267-77. (PMID: 17227978)
Radiother Oncol. 2005 Jul;76(1):48-53. (PMID: 15990186)
Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):124-8. (PMID: 9711744)
Cancer. 2009 Feb 1;115(3):665-72. (PMID: 19117351)
Ann Surg. 2006 Aug;244(2):332-3; author reply 333. (PMID: 16858208)
Clin Oncol (R Coll Radiol). 2010 Apr;22(3):157-72. (PMID: 20092981)
J Clin Oncol. 2011 Nov 1;29(31):4105-12. (PMID: 21969502)
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3. (PMID: 16168826)
Cancer. 1990 Jul 1;66(1):56-61. (PMID: 2354408)
Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4. (PMID: 10615932)
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1456-61. (PMID: 19783379)
Am J Clin Oncol. 2011 Feb;34(1):63-9. (PMID: 20308870)
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1231-9. (PMID: 8262852)
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1420-5. (PMID: 20056345)
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21. (PMID: 15001240)
JAMA. 2008 Mar 5;299(9):1019-26. (PMID: 18319412)
Gastrointest Endosc. 2006 Sep;64(3):412-7. (PMID: 16923491)
Entry Date(s):
Date Created: 20120522 Date Completed: 20130125 Latest Revision: 20220408
Update Code:
20240104
PubMed Central ID:
PMC3441204
DOI:
10.1186/1748-717X-7-74
PMID:
22607687
Czasopismo naukowe
Background: Local control rates are poor in the treatment of pancreatic cancer. We investigated the role of hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses of external beam radiation therapy.
Methods: All patients treated with SBRT for pancreatic adenocarcinoma at Georgetown University from June 2002 through July 2007 were examined. Eligible patients had prior external beam radiation therapy to the pancreas. Treatment parameters and clinical and radiographic follow-up were evaluated.
Results: Twenty-eight patients were identified who received SBRT after a median prior external beam radiotherapy dose of 50.4 Gy. The median patient age was 63 years old and the median follow-up was 5.9 months. Twelve of fourteen (85.7%) evaluable patients were free from local progression, with three partial responses and nine patients with stable disease. Toxicity consisted of one case of acute Grade II nausea/vomiting, and two cases of Grade III late GI toxicity. The median overall survival was 5.9 months, with 18% survival and 70% freedom from local progression at one year.
Conclusions: Hypofractionated SBRT reirradiation of localized pancreatic cancer is a well-tolerated treatment. Most patients are free from local progression, albeit with limited follow-up, but overall survival remains poor.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies